Mr. Michael Frank reports

REVIVE THERAPEUTICS ANNOUNCES CLOSING OF SECOND TRANCHE OF PRIVATE PLACEMENT

Revive Therapeutics Ltd. has closed a second tranche of its previously announced private placement (see news release of Sept. 5, 2025) by issuing 4,352,381 units, at a price of 2.1 cents per unit, for gross proceeds to Revive of $91,400.

Each unit comprises one common share of the company and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at an exercise price of five cents for a period of 36 months following the closing.

The gross proceeds from the private placement offering will be used for working capital and payment of certain trade payables.

All of the securities issued are subject to a hold period of four months and one day expiring on Jan. 19, 2026.

About Revive Therapeutics Ltd.

Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage U.S. Food and Drug Administration (FDA) regulatory incentives like emergency use authorization, orphan drug, fast-track and breakthrough therapy designations, positioning for rapid advancement and market entry. Currently, the company's efforts are concentrated on unlocking the vast potential of bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing its psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science.

We seek Safe Harbor.